SHANGHAI – Yabao Pharmaceutical Co. Inc. has agreed to co-develop with Le Sun Pharmaceutical Ltd. their leading PLK/PI3K dual inhibitor LS-008. On its hunt to find candidates with global potential, Chinese pharma Yabao will team up with the local biotech to accelerate development for the preclinical oncology candidate.